Comparative pharmacoeconomic analysis on analgesics consumption in the Republic of Serbia and Nordic countries in the period 2015-2018
Abstract
Introduction: Analgesics are drugs used in the pain pharmacotherapy and are one of the most prescribed drugs in all countries. Modern pain pharmacotherapy involves the use of analgesic steps.
Objective: The objective of this work was to analyze the consumption of drugs used in the pain pharmacotherapy in the Republic of Serbia (RS), in the period from 2015 to 2018, and to compare the obtained results with the consumption of the mentioned drugs in the Kingdom of Norway (KN) and the Republic of Finland (RF) in the same time period interval.
Material and methods: Data on drug consumption were taken from the website of the Agency for Medicines and Medical Devices of Serbia, official website of the Norwegian Institute of Public Health and from the official website of the Finnish Medicines Agency. The consumption of medicines is monitored using the Defined Daily Dose (DDD) methodology.
Results: Paracetamol consumption was 13 to even 20 times lower in the RS compared to the KN and 10 to 15 times lower compared to the RF. The average consumption of diclofenac during the 4 observed years was about 30 in the RS, about 7 in the KN and about 4 DDD/1000 inhabitants/day in the RF.
Conclusion: In the pain pharmacotherapy in the RS, the consumption of non-steroidal anti-inflammatory drugs is dominated by diclofenac, while in the KN and the RF ibuprofen and paracetamol from non-opioids.
References
1.1. Aydede M. Does the IASP definition of pain need updating? Pain Rep 2019; 4(5): e777. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882577/
2. 2. Republička stručna komisija za izradu i implementaciju vodiča u kliničkoj praksi; Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje hroničnog bola maligne etiologije. Ministarstvo zdravlja Republike Srbije: Beograd, 2013. https://www.zdravlje.gov.rs/view_file.php?file_id=556&cache=sr
3. 3. Danilov A, Danilov A, Barulin A, Kurushina O, Latysheva N. Interdisciplinary approach to chronic pain management. Postgrad Med 2020; 132(Suppl 3): 5-9. https://www.tandfonline.com/doi/abs/10.1080/00325481.2020.1757305?journalCode=ipgm20
4. 4. Stevanović P, Nešić D, Lađević N et al. Medicina bola. CIBID, Medicinski fakultet, Univerzitet u Beogradu, Beograd, 2020.
5. 5. Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm 2014; 71(1): 11-23. https://www.ptfarm.pl/pub/File/Acta_Poloniae/2014/1/011.pdf
6. 6. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem 2012; 11(1): 52-64. https://pubmed.ncbi.nlm.nih.gov/22934743/
7. 7. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res 2013; 191: 67-93. https://pubmed.ncbi.nlm.nih.gov/22893200/
8. 8. Oldham JM. Opioids. J Psychiatr Pract 2020; 26(1): 1-2. https://journals.lww.com/practicalpsychiatry/Fulltext/2020/01000/Opioids.1.aspx
9. 9. Portenoy RK. A Practical Approach to Using Adjuvant Analgesics in Older Adults. J Am Geriatr Soc 2020; 68(4): 691-698. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.16340
10. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2015. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2016. https://www.alims.gov.rs/wp-content/uploads/2022/01/011-Promet-lekova-2015.pdf
11. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2016. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2017. https://www.alims.gov.rs/wp-content/uploads/2022/01/PPL2017.pdf
12. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2017. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2018. https://www.alims.gov.rs/wp-content/uploads/2022/01/PPL2017.pdf
13. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2018. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2019. https://www.alims.gov.rs/wp-content/uploads/2022/01/PPL_2019.pdf
14. Norwegian Institute for Public Health. Drug Consumption in Norway 2015-2018. Oslo: Norwegian Institute for Public Health; 2023. http://www.legemiddelforbruk.no/english/
15. Finnish Medicines Agency Fimea. Finnish Statistics on Medicines 2015-2018. Helsinki: Finnish Medicines Agency Fimea; 2023. http://raportit.nam.fi/raportit/kulutus/laakekulutus_e.pdf
16. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2022. Oslo, Norway 2021. https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/
17. Tomić Z, Sabo A, Horvat O, Milijašević B. Osnovi farmakoekonomije i farmakoepidemiologije. Medicinski fakultet Novi Sad: Novi Sad, 2020.
18. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11 (2 Suppl): S133-153. https://www.painphysicianjournal.com/current/pdf?article=OTg3&journal=42
19. Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician 2015; 18(4): 395-400. https://www.painphysicianjournal.com/current/pdf?article=MjM3OA%3D%3D&journal=89
20. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin 2010; 26(7): 1715-1731. https://www.tandfonline.com/doi/abs/10.1185/03007995.2010.486301?journalCode=icmo20
21. Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications. Zhonghua Nei Ke Za Zhi 2017; 56(1): 81-85. https://pubmed.ncbi.nlm.nih.gov/32146743/
22. Irvine J, Afrose A, Islam N. Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Dev Ind Pharm 2018; 44(2): 173-183. https://www.tandfonline.com/doi/abs/10.1080/03639045.2017.1391838?journalCode=iddi20
23. Singla AK, Chawla M, Singh A. Nimesulide: some pharmaceutical and pharmacological aspects--an update. J Pharm Pharmacol 2000; 52(5): 467-486. https://academic.oup.com/jpp/article/52/5/467/6157532?login=false
24. Ha MW, Paek SM. Recent Advances in the Synthesis of Ibuprofen and Naproxen. Molecules 2021; 26(16): 4792. https://www.mdpi.com/1420-3049/26/16/4792
25. Gatti D, Adami S. Coxibs: a significant therapeutic opportunity. Acta Biomed 2010; 81(3): 217-224. https://pubmed.ncbi.nlm.nih.gov/22530460/